ipamorelin mastery course
Unit 6 of 11

what the trials actually show

one negative RCT, one PK study, and a lot of preclinical extrapolation

the single most important fact in this dossier

The only published Phase II efficacy RCT of ipamorelin -- Beck 2014, multicenter, 114 randomized adults, postoperative ileus, Helsinn-sponsored -- was negative on its primary endpoint. The trial confirmed acceptable safety but showed no separation from placebo on time-to-bowel-movement or solid-food tolerance. Helsinn discontinued. Earlier, Novo Nordisk had already walked away after Phase I/IIa. The Gobburu 1999 paper that community materials often cite as "Phase II evidence" was a healthy-volunteer pharmacokinetics study, not an efficacy trial. Every clinical claim in the community space rests on mechanism extrapolation, not outcome data.

trial timeline -- 1996 to 2024

click any milestone for design, n, primary endpoint, finding, and what it means for community use. arrow keys cycle, Enter pins.

ipamorelin clinical-evidence timeline

evidence-tier ladder

where each milestone actually sits -- vs where community materials imply it sits.

evidence tier ladder

key terms

tap to expand.

RRCTtrial design
randomized controlled trial -- the gold-standard trial design where participants are assigned to drug or placebo by chance, ideally with double-blinding. Beck 2014 was an RCT. Gobburu 1999 was a single-arm PK study with placebo controls but not powered for efficacy.
Pprimary endpointtrial design
the pre-specified outcome a trial is designed to test. for Beck 2014, the primary endpoint was a GI-2 composite -- time to first bowel movement and tolerance of solid food. ipamorelin did not separate from placebo on this endpoint.
Ppostoperative ileuscondition
the transient paralysis of the GI tract after abdominal surgery that delays the return of bowel function. ghrelin-mimetic prokinetic action was the mechanistic rationale for testing ipamorelin in this indication. rodent ileus models predicted benefit; the human trial did not replicate it.
NNCT00672074trial ID
the ClinicalTrials.gov registration for the Helsinn ipamorelin postoperative-ileus trial. registered 2008, completed and reported as Beck 2014. NCT01280344 is the companion / extension registration.
Mmechanism extrapolationevidence type
reasoning from a known mechanism to a presumed clinical effect, without an actual outcome trial in the target population. all current community claims for ipamorelin in body composition, anti-aging, recovery, and sleep rest on mechanism extrapolation. the FDA PCAC briefing flagged this pattern in its 2024 vote.
GGobburu 1999paper
Gobburu et al. Pharm Res 1999 (PMID 10496658) -- a 48-volunteer healthy-male PK-PD study. it is the source of the well-known 2-hour half-life and dose-proportional GH-pulse data. it is not an efficacy trial in GH-deficient adults and was never represented as one by the original authors.

what the trials say -- the simple version

three studies, three different things to say about them.

There are three published human-data points worth knowing. The first is Gobburu 1999. This was a careful Phase I pharmacokinetics study in 48 healthy male volunteers. It tells you ipamorelin has a roughly two-hour half-life and produces a dose-proportional GH pulse. It does not tell you anything about whether ipamorelin treats a disease.

The second is Beck 2014. This was the only published Phase II efficacy RCT, run by Helsinn in 114 adults recovering from bowel surgery. The trial was well-designed and well-conducted -- ipamorelin was well-tolerated. But on the primary endpoint, the drug did not separate from placebo. Helsinn discontinued the program. This is the most important single fact about ipamorelin's clinical record, and it is consistently glossed over in community materials.

The third "data point" is the absence of data. There is no published RCT in body composition. No published RCT in sleep or recovery. No published RCT in adult GH deficiency. No published RCT in sarcopenia or anti-aging. Every claim in those spaces is mechanism extrapolation -- reasoning from "ipamorelin causes a GH pulse" to "ipamorelin produces a clinical outcome."

Aadvanced: Beck 2014 design and outcome detailclinical
Helsinn Therapeutics multicenter Phase II, double-blind, placebo-controlled. 114 evaluable adults undergoing open or laparoscopic small/large bowel resection. intervention: IV ipamorelin 0.03 mg/kg twice daily vs placebo, postoperative day 1 through 7 or hospital discharge. primary endpoint: GI-2 composite (time to first bowel movement and tolerance of solid food). result: well-tolerated, no significant difference vs placebo on primary or key secondary efficacy endpoints. published in Int J Colorectal Dis 2014 (PMID 25331030). mechanistic rationale -- ghrelin-mimetic prokinetic effect -- had been supported by Greenwood-Van Meerveld rodent ileus models, consistent with the broader pattern of rodent-to-human GI-motility translational failure.
advanced: the Gobburu misuse pattern in community materials
community sources routinely cite Gobburu 1999 as "the Novo Nordisk Phase II GH-deficiency trial." this is wrong on three counts: the trial was Phase I, not Phase II; the population was healthy volunteers, not GH-deficient adults; and the endpoint was pharmacokinetic, not clinical. the FDA briefing document for the 2024 PCAC vote (FDA-2024-N-4188) explicitly notes that nominators citing Gobburu to support a GH-deficiency indication are misrepresenting the trial population. if you see "Phase II in adult GHD" cited for ipamorelin, it is shorthand for "Novo had a development program that did not progress to a published efficacy trial" -- not for a positive Phase II result.
advanced: preclinical body-composition and bone data tiers
Johansen et al. Eur J Endocrinol 1999 (PMID 10373343) showed 21-day chronic ipamorelin in young female rats increased body-weight gain and ex-vivo pituitary GH release. Svensson et al. J Endocrinol 2000 (PMID 10828840) showed 12-week continuous subcutaneous infusion of ipamorelin 0.5 mg/kg/day in adult female rats increased total tibial and vertebral bone mineral content; total BMC corrected for body weight was unchanged. Svensson et al. 2003 showed ipamorelin partially counteracted glucocorticoid-induced bone-formation reductions. all three are animal data. translation caveats include continuous-infusion dosing (not the pattern used in humans) and species-specific GH-axis biology.
Beck 2014 named callout. the only published Phase II efficacy RCT of ipamorelin -- multicenter, double-blind, placebo-controlled, 114 randomized adults in postoperative ileus -- was negative on its primary endpoint. Helsinn discontinued the program after the result. this is the single most important fact in the entire ipamorelin literature.
Gobburu mis-citation correction. Gobburu 1999 was a healthy-volunteer pharmacokinetics trial. it was not a Phase II GH-deficiency efficacy trial. the FDA briefing document for the 2024 PCAC vote explicitly flags this misuse pattern in community materials.

where this has been studied

the published human and preclinical trail.

Phase I PK (Gobburu 1999)
48 healthy male volunteers, IV infusion across 33-fold dose range. dose-proportional PK, GH pulse Cmax 20-223 mU/L, terminal half-life ~2 hours. acute safety was acceptable. this is the most-cited paper in the literature -- and the most-misrepresented.
Phase II ileus (Beck 2014)
114 randomized adults, multicenter, double-blind. IV ipamorelin 0.03 mg/kg BID for up to 7 days vs placebo. negative on primary GI-2 endpoint. PMID 25331030. Helsinn discontinued.
preclinical bone/body comp
Svensson 2000 (PMID 10828840), Johansen 1999 (PMID 10373343), Svensson 2003 -- rat continuous-infusion studies showing bone mineral content and longitudinal growth effects. animal-level data; continuous-infusion dosing differs from human pulsatile patterns.
community-target indications
no peer-reviewed open-label clinical series in body composition, sleep, recovery, or anti-aging endpoints has been published. the single largest gap between mechanism enthusiasm and clinical evidence.